Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs
Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs
About this item
Full title
Author / Creator
Publisher
United States: Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
United States: Public Library of Science
Subjects
More information
Scope and Contents
Contents
First line chemotherapeutics for brain tumors (malignant gliomas) are alkylating agents such as temozolomide and nimustine. Despite growing knowledge of how these agents work, patients suffering from this malignancy still face a dismal prognosis. Alkylating agents target DNA, forming the killing lesion O(6)-alkylguanine, which is converted into DNA...
Alternative Titles
Full title
Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_plos_journals_1310424926
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_1310424926
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0027183
